Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...TOLEDO recently announced that a free webinar, &ld...At-Line Particle Characterization”, will be ...he application of in situ particle characterizatio...mize a series of roller compaction runs while vary...on forces. , (PRWEB) Nove...
(Date:11/19/2009)... Dr. Mate Hidvegi, inventor of Ave...ess release issued on November 17 by Biropharma Kf...alse and self-serving statements about its U.S. co...stated from his office in Budapest, Hungary: ,...es not apply to AveULTRA, www.aveultra.com , is...
(Date:11/19/2009)..., November 19 MONITORING FORCE Gmb... 2009 Flibanserin in the,indication treatment-rele...sease for orphan drug status designation with the ... dyskinesia is a complication of the mainstay,trea... to some of those,affected, since it may be disabl...
(Date:11/19/2009)..., November 19 AFFiRiS AG will focu...andidate at an unexpectedly early,stage of develop...er into,Phase II clinical trial early in 2010. Thi...completion of two Phase I trials with the candidat...ion on the first interim,analysis of the secondary...
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...ts Senior Management Team with Recent Strategic Hi..., Puerto Rico, May 14 Triple-S,Management Corpora...ll-Rodriguez, MD, medical director at the San Jorg...or the Children,s Oncology Group and,the Dana Farb...pointed,chairman of the board of directors. He has...
...Vista Partners announced today that,it has initiat... SYI ). Ross,Silver, Director of Research of Vista...ll cap investment opportunities investors will com...rials in multi-billion dollar markets.,Additionall...could begin to,produce revenues as early as next y...
...14 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ...t and CEO, Chris,Waddick, will present a Company o...Healthcare Conference in Monte Carlo, at 12:30 p.m...8., A live webcast of the presentation can be acc...ogen.com . An archived replay will also be availab...
Other Biology Technology:Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference 3
(Date:11/20/2009)... a respiratory disease commonly known as chronic b...e of death worldwide. 600 million people live wit...real treatment or cure, Grace Parraga of Robarts R...ario in London, Canada, is using various imaging t... , Parraga is a scientist in the Imaging Resear...
(Date:11/20/2009)...report that a class of heart medications called be... on the heart, depending on their molecular activi...irculation Research , found that beta-blockers tha... heart muscle offer the most benefit to cardiac pa...ptors can actually undermine the structure and fun...
(Date:11/19/2009)... of the last ice age, North America,s vast assembl...res as mammoths, mastodons, camels, horses, ground... slide to extinction. , And when their populatio...ge animals equaled or surpassed Africa,s wildlife-...el ecosystem emerged as broadleaved trees once kep...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Carvedilol shown to have unique characteristics among beta blockers 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3When H1N1 Hits Communication From Schools to Parents is Critical 57618 1When H1N1 Hits Communication From Schools to Parents is Critical 57618 2When H1N1 Hits Communication From Schools to Parents is Critical 57618 3More People Say Medical Conditions Make it Difficult To Find a Job or Remain Employed 57615 1More People Say Medical Conditions Make it Difficult To Find a Job or Remain Employed 57615 24 Stair Lifts Announces Grand Opening of Online Store 57610 14 Stair Lifts Announces Grand Opening of Online Store 57610 2
...search Foundation (CRF) brings experts to New York...International Conference on Cell Therapy for Cardi...his emerging field, the three-day session will fea...r myocardial repair and regeneration, angiogenesis...s include: , Clinical Focus: Full-day programs...
...f the journal Emerging Infectious Diseases, Swedis...perboreal tundra, in connection with the tundra ex...cs-resistant bacteria. These findings indicate th...e, which is an alarming prospect for future health...s in northeastern Siberia, northern Alaska, and no...
...11, 2008): Nucleonics, Inc., a privately held bio...ovel RNA interference (RNAi)-based therapeutics, a... patients in a Phase 1 human safety study of its e...s (HBV) infection, NUC B1000. , NUC B1000 ( http...n expressed interfering RNA (eiRNA)-based product ...
Other Biology News:Cell Therapy for Cardiovascular Diseases 2Cell Therapy for Cardiovascular Diseases 3High degree of resistance to antibiotics in Arctic birds 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3
... Rabbit polyclonal to Kv4.2 Immunogen Synthetic ... corresponding to amino acids 23-43 of Rat Kv4.2. ...xpected to cross-react with Human (100% identity w...n), Rabbit (100% identity with immunogen) and Ferr...
...oclonal [198C679.2.1] to Presenilin 2 Alzheimer's...he disease carry mutations in the presenilin prote...n (APP). These disease-linked mutations result in ...-beta (main component of amyloid deposits found in...
XTT (23-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) from Molecular Probes (Invitrogen)
2-Fluorine-CTP (2-F-CTP) from EPICENTRE Biotechnologies
Biology Products: